COVID-19 Worsens Neurological Problems, Delirium
At AD/PD 2021, clinicians discussed neurological symptoms and brain tissue damage in older people who died from COVID-19.
6494 RESULTS
Sort By:
At AD/PD 2021, clinicians discussed neurological symptoms and brain tissue damage in older people who died from COVID-19.
By shifting to home nursing and telemedicine, clinical researchers kept inching ahead during lockdowns.
In cell culture, neurons with the strongest expression of cell-cycle proteins survived best in the presence of Aβ oligomers.
Herpes infection upped risk in ApoE4 carriers, damaged brain tissue, and correlated with neurodegeneration markers in the CSF.
Sending low-intensity, gamma frequency electric current through the brain boosted short-term memory, perhaps by increasing cholinergic transmission.
A new trial will compare digital and blood-based biomarkers to amyloid PET scans in order to learn which ones best pick out early plaque accumulation.
The tau vaccine evoked a robust anti-tau antibody response, which curbed the rise in plasma NfL and CSF p-tau over two years. Cognitive decline continued.
Though the first two trial arms were negative on cognition, gantenerumab’s strong effect on biomarkers led to an open-label extension.
Aducanumab: Will Appropriate-Use Recommendations Speed Uptake? On Donanemab, Plaques Plummet. Off Donanemab, They Stay Away Antisense Therapy Stifles CSF Tau in Mild Alzheimer’s Disease Seeking Real-World Data on Whether Aducanumab Works Will Insurance Co
In the wake of the controversial thumbs-up for Aduhelm, the U.S. federal government is probing not only aducanumab’s price and approval history, but also the FDA’s accelerated approval pathway in general.
In an open-label Phase 2 study, fluid biomarkers suggested the anti-sortilin antibody restored lysosomal function and reduced neuroinflammation in people with symptomatic FTD. Tantalizingly, participants worsened less than historical controls.
Topline results from a Phase 2 trial of semorinemab suggest the therapeutic antibody may have eased the cognitive downturn in people with mild to moderate Alzheimer’s disease.
Markers of neuronal injury rose in plasma within a few months of severe COVID-19, then fell back to normal by six months. Some cases with brain symptoms had lower Aβ and higher tau in their blood.
North Carolina and South Texas centers to focus on risk factors and diversity.
Misfolded tau travels from a subset of neurons in the entorhinal cortex directly into CA1 neurons in the hippocampus, fouling synaptic transmission and memory in mice.
No filters selected